Details of the Company’s subsidiaries which
are included in these consolidated financial statements as of December 31, 2025 are as follows:
| Name of Subsidiary | | Place and date of Incorporation | | Percentage of Ownership | | Principal Activities | | Avalon Healthcare System, Inc. (“AHS”) | | Delaware
May 18, 2015 | | 100% held by ALBT | | Holding company for payroll and other expenses | | | | | | | | | | Avalon RT 9 Properties LLC (“Avalon RT 9”) | | New Jersey
February 7, 2017 | | 100% held by ALBT | | Owned and operated an income-producing real property and held and managed the corporate headquarters through February 2026 | | | | | | | | | | Avalon (Shanghai) Healthcare Technology Co., Ltd. (“Avalon Shanghai”) | | PRC
April 29, 2016 | | 100% held by AHS | | Is not considered an operating entity | | Genexosome Technologies Inc. (“Genexosome”) | | Nevada
July 31, 2017 | | 60% held by ALBT | | No current activities to report, dormant | | Avalon Laboratory Services, Inc. (“Avalon Lab”) | | Delaware
October 14, 2022 | | 100% held by ALBT | | No current activities to report, dormant | | Q&A Distribution LLC (“Q&A Distribution”) | | Texas
May 1, 2024 | | 100% held by ALBT | | Distributes KetoAir device | | Nexus MergerSub Limited (“Nexus”) | | BVI
February 21, 2025 | | 100% held by ALBT | | No current activities to report | | Avalon Quantum AI, LLC (“Avalon Quantum AI”) | | Nevada
December 5, 2025 | | 100% held by ALBT | | Advanced Agentic AI systems, including automated video generation and workflow automation solutions." |
|